Effect of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy

Chronic central serous chorioretinopathy

  • Omer Farooq
  • Asad Habib PNS shifa karachi
  • Masood Alam Shah
  • Najia Ahmed
Keywords: Central serous retinopathy, Eplerenone, Mineralocorticoids, Subretinal fluid

Abstract

Objective: To determine the efficacy of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy (CSCR).

Methods: This quasi experimental study was performed at PNS Shifa Hospital Karachi from September 2018 to February 2019. Study included 23 patients. Patients were included using consecutive sampling technique and informed consent was taken from all patients before staring treatment. 50 mg of oral eplerenone per day was given for three months. Subretinal fluid (SRF) height and visual acuity (VA) were noted at baseline, one month and three month follow-up. Structured Study performa was used for data collection. Data was analysed and assessed with SPSS version 23. P value of <0.05 was considered statistically significant.

Results: Mean age of patients was 40.7±7 years and mean duration of disease before treatment was 3.7±0.76 months. Mean baseline BCVA and SRF height was 0.39±0.02 logMAR and 123±12.5 µm respectively. Sixty-five percent patients responded at one month and 80% at three months with reduction in SRF height. Improvement in visual acuity was also statistically significant at 3 months (p<0.05).

Conclusion: Use of eplerenone in chronic CSCR resulted in significant improvement in vision and decrease in mean SRF height.

doi: https://doi.org/10.12669/pjms.35.6.896

How to cite this:
Farooq O, Habib A, Shah MA, Ahmed N. Effect of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy. Pak J Med Sci. 2019;35(6):1544-1547. doi: https://doi.org/10.12669/pjms.35.6.896

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published
2019-10-07
Section
Original Articles